Solid Biosciences, Inc. (SLDB)
6.92
-0.14
(-1.98%)
USD |
NASDAQ |
Oct 06, 16:00
6.91
-0.01
(-0.14%)
Pre-Market: 20:00
Solid Biosciences Enterprise Value : 369.31M for Oct. 6, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| October 06, 2026 | 369.31M |
| October 05, 2026 | 384.02M |
| October 02, 2026 | 361.95M |
| October 01, 2026 | 375.61M |
| September 30, 2026 | 401.90M |
| September 29, 2026 | 394.54M |
| September 28, 2026 | 407.15M |
| September 25, 2026 | 408.20M |
| September 24, 2026 | 428.18M |
| September 23, 2026 | 484.94M |
| September 22, 2026 | 579.56M |
| September 21, 2026 | 539.61M |
| September 18, 2026 | 578.51M |
| September 17, 2026 | 574.30M |
| September 16, 2026 | 558.53M |
| September 15, 2026 | 521.74M |
| September 14, 2026 | 560.64M |
| September 11, 2026 | 556.43M |
| September 10, 2026 | 595.33M |
| September 09, 2026 | 644.74M |
| September 08, 2026 | 685.73M |
| September 04, 2026 | 719.37M |
| September 03, 2026 | 737.25M |
| September 02, 2026 | 723.05M |
| September 01, 2026 | 680.48M |
| Date | Value |
|---|---|
| August 31, 2026 | 648.94M |
| August 28, 2026 | 668.91M |
| August 27, 2026 | 706.76M |
| August 26, 2026 | 663.66M |
| August 25, 2026 | 681.53M |
| August 24, 2026 | 604.79M |
| August 21, 2026 | 619.51M |
| August 20, 2026 | 598.48M |
| August 19, 2026 | 665.76M |
| August 18, 2026 | 596.38M |
| August 17, 2026 | 598.48M |
| August 14, 2026 | 608.99M |
| August 13, 2026 | 596.38M |
| August 12, 2026 | 594.80M |
| August 11, 2026 | 572.20M |
| August 10, 2026 | 541.71M |
| August 07, 2026 | 523.84M |
| August 06, 2026 | 557.48M |
| August 05, 2026 | 559.58M |
| August 04, 2026 | 548.02M |
| August 03, 2026 | 484.94M |
| July 31, 2026 | 489.15M |
| July 30, 2026 | 534.35M |
| July 29, 2026 | 487.05M |
| July 28, 2026 | 479.69M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Agenus, Inc. | 583.85M |
| Amgen, Inc. | 260.96B |
| BioCryst Pharmaceuticals, Inc. | 2.513B |
| Imunon, Inc. | 6.206M |
| Curis, Inc. | -3.113M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -54.80M |
| Total Expenses (Quarterly) | 54.80M |
| EPS Diluted (Quarterly) | -0.3814 |
| Earnings Yield | -27.58% |
| Normalized Earnings Yield | -26.99 |